Organovo Holdings, Inc. (ONVO), a clinical-stage biotech firm focused on advancing innovative treatments for inflammatory bowel disease, on Monday announced the appointment of Norman Staskey as its Chief Financial Officer (CFO).
Staskey joins from Danforth Advisors, where he has served since 2021, providing CFO services to clients like Azitra, Inc.
Currently, ONVO is trading at $0.48 up 7.15 percent or $0.032 on the Nasdaq.
For comments and feedback: editorial@rttnews.com